ReviewCNS drugs2012
Taking the negative view of current migraine treatments: the unmet needs.
Review in CNS drugs, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Safety evaluation of oral calcitonin-gene-related peptide receptor antagonists in patients with acute migraine: a systematic review and meta-analysis.European journal of clinical pharmacology · 2022Pooled it
- Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles.Nature genetics · 2022Pooled it
- Comparative Efficacy of Oral Calcitonin-Gene-Related Peptide Antagonists for the Treatment of Acute Migraine: Updated Meta-analysis.Clinical drug investigation · 2021Pooled it
- Sishun Formula for acute migraine attack: study protocol for a double-blind, randomized, placebo-controlled trial.Frontiers in neurology · 2025Article
- Validation and comparison of the coding algorithms to identify people with migraine using Japanese claims data.Frontiers in neurology · 2023Article
- The ATP sensitive potassium channel (KFrontiers in molecular neuroscience · 2023Review
- Low adherence to the guideline for the acute treatment of migraine.Scientific reports · 2022Article
- Why is the therapeutic effect of acute antimigraine drugs delayed? A review of controlled trials and hypotheses about the delay of effect.British journal of clinical pharmacology · 2019Review
- CGRP and the Trigeminal System in Migraine.Headache · 2019Review
- Microglial NLRP3 inflammasome activation mediates IL-1β release and contributes to central sensitization in a recurrent nitroglycerin-induced migraine model.Journal of neuroinflammation · 2019Article
- A novel large animal model of recurrent migraine established by repeated administration of inflammatory soup into the dura mater of the rhesus monkey.Neural regeneration research · 2019Article
- Soluble guanylyl cyclase is a critical regulator of migraine-associated pain.Cephalalgia : an international journal of headache · 2018Article
- PACAP and its receptors in cranial arteries and mast cells.The journal of headache and pain · 2018Review
- Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential.Journal of pain research · 2018Review
- Increased intrinsic brain connectivity between pons and somatosensory cortex during attacks of migraine with aura.Human brain mapping · 2017Article
- Review
- Neurovascular contributions to migraine: Moving beyond vasodilation.Neuroscience · 2016Review
- Mechanisms mediating nitroglycerin-induced delayed-onset hyperalgesia in the rat.Neuroscience · 2016Article
- Article
- Calcitonin gene-related peptide (CGRP): a new target for migraine.Annual review of pharmacology and toxicology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute migraine treatment is given to abolish ongoing attacks, while prophylactic migraine treatment is given on a daily basis to prevent the occurrence of migraine attacks as far as possible. The majority of migraine patients do not use the specific acute anti-migraine drugs, the triptans. Thus, only 10% (Denmark) to 35% (France) of migraine patients use triptans. This is most likely due to relatively low efficacy. Thus, in randomized controlled trials (RCTs) pain freedom after 2 hours ranges from 12% (frovatriptan 2.5 mg) to 40% (rizatriptan 10 mg). For prophylactic treatment (propranolol, valproate, topiramate) a response (at least a 50% reduction in migraine frequency) is observed in 40-50%. In addition, prophylactic treatment is hampered by adverse events and withdrawals. There is a need for new acute anti-migraine drugs and targets are already available and there are more to come. It has been estimated that approximately 2% of the adult population need prophylactic treatment because of frequent migraine attacks. For prophylactic migraine drugs there is an even greater need for new drugs than for acute drug treatment.
Indexed as
Identifiers
22519921What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.